LABA/LAMA FDC (N = 292) | Triple therapy (N = 675) | |
---|---|---|
During the 12 months prior to baseline | ||
Patients with ≥ 1 COPD exacerbation, n (%) | 127 (43.5) | 330 (48.9) |
p value | 0.123 | |
Number of exacerbations, n (%) | ||
0 | 165 (56.5) | 345 (51.1) |
1 | 108 (37.0) | 214 (31.7) |
2 | 19 (6.5) | 81 (12.0) |
≥ 3 | 0 (0.0) | 35 (5.2) |
During the study | ||
Patients with ≥ 1 COPD exacerbation, n (%) | 54 (18.5) | 194 (28.7) |
p value | < 0.001 | |
Number of exacerbations, n (%) | ||
0 | 238 (81.5) | 481 (71.3) |
1 | 45 (15.4) | 127 (18.8) |
2 | 9 (3.1) | 43 (6.4) |
≥ 3 | 0 (0.0) | 24 (3.6) |
Annualised exacerbation rate during the study (95% confidence limit) | 0.212 (0.164, 0.274) | 0.436 (0.375, 0.507) |